MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Rezolute General and Administrative Expenses 2011-2026 | RZLT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Rezolute
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.4 M | 14.7 M | 12.2 M | 9.36 M | 7.91 M | 6.07 M | 6.82 M | 9.1 M | 8.23 M | 5.5 M | 6 M | 5.13 M | 6.1 M | 42.7 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.4 M | 42.7 K | 8.25 M |
Quarterly General and Administrative Expenses Rezolute
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.87 M | 6.67 M | - | 4.74 M | 4.45 M | 4.19 M | - | 3.81 M | 3.16 M | 3.7 M | - | 2.91 M | 3.45 M | 2.51 M | 5.96 M | 2.07 M | 2.7 M | 1.87 M | 4.56 M | 1.72 M | 2.66 M | 1.28 M | 2.66 M | 1.28 M | 1.68 M | 1.94 M | 1.68 M | 420 K | 292 K | 239 K | 531 K | 414 K | 318 K | 328 K | 318 K | 328 K | 302 K | 257 K | 302 K | 257 K | 198 K | 205 K | 198 K | 205 K | 184 K | 356 K | 184 K | 553 K | 80.5 K | 17.4 K | 7.54 K | 19.5 K | 23.2 K | 5.01 K | 9.31 K | 3.53 K | 8 K | 7.39 K | 8 K | 7.39 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.87 M | 3.53 K | 1.55 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.88 | -1.69 % | $ 6.47 M |  China |
 |
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.1 | - | $ 438 M |  USA |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 9.59 | - | $ 620 M | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M | China |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 4.92 | - | $ 781 M | Britain |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 22.45 | - | $ 3.72 B | USA |
 |
Cerus Corporation
CERS
|
80.9 M | $ 2.03 | - | $ 387 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
52 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
12.1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
286 M | $ 103.45 | - | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
136 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
49.9 M | $ 3.0 | - | $ 266 M | USA |
 |
Innate Pharma S.A.
IPHA
|
25.5 M | $ 1.44 | -3.36 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Evogene Ltd.
EVGN
|
7.25 M | $ 0.78 | - | $ 27.9 M | Israel |
 |
Edesa Biotech
EDSA
|
4.13 M | $ 18.27 | - | $ 58.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.19 | 1.27 % | $ 5.25 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
25.2 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
10.7 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |